2. Search Result
Search Result
Results for "

9l-cell

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

4

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17602
    Amcasertib

    BBI503

    		 Apoptosis Cancer
    Amcasertib (BBI503) is an orally activate cancer stemness kinase inhibitor that enhances apoptosis. Amcasertib inhibits the expression of NANOG and CD133 and cell viability in PC-9/GR cells.
    Amcasertib
  • HY-100738
    Ubiquitin Isopeptidase Inhibitor I, G5
    5+ Cited Publications

    NSC144303

    		 Apoptosis Cancer
    Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent caspase and apoptosis activator with IC50 values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.
    Ubiquitin Isopeptidase Inhibitor I, G5
  • HY-110381
    JNJ-DGAT2-A

    		Acyltransferase Metabolic Disease
    JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .
    JNJ-DGAT2-A
  • HY-178955
    EGFR-IN-182

    		EGFR HSP PI3K Caspase Apoptosis CDK ERK Akt Cancer
    EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer .
    EGFR-IN-182
  • HY-N7006
    Timosaponin C

    Anemarsaponin C

    		 Others Inflammation/Immunology
    Timosaponin C is isolated from Rhizoma Anemarrhenae . Timosaponin C shows weaker NO inhibition in N9 microglial cells .
    Timosaponin C
  • HY-149001
    PARP1-IN-9

    		PARP Cancer
    PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC50 of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .
    PARP1-IN-9
  • HY-178485
    SJY26

    		PI3K HDAC Akt Histone Methyltransferase Cancer
    SJY26 is a PI3K/HDAC dual-target inhibitor with IC50s of 0.59 nM (PI3Kα and PI3Kδ), 2.02 nM (PI3Kγ), 12.69 nM (PI3Kβ) and 114 nM (HDAC1). SJY26 exhibits potent broad-spectrum anti-proliferative activity, and is particularly sensitive to Jurkat and PC9R cells. SJY26 inhibited the migration of PC9R cells, arrested the cell cycle and induced cell apoptosis. SJY26 reduces AKT phosphorylation, and decreases histone H3 deacetylation (Ac-H3). SJY26 can be used for the studies of non-small cell lung cancer and leukemia .
    SJY26
  • HY-131244
    ALK-IN-9

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-9 (compound 40) is a potent ALK inhibitor. ALK-IN-9 inhibits cell proliferation with IC50s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-l cell (OP2-FGFR1), respectively .
    ALK-IN-9
  • HY-178474
    WRN-IN-20

    		DNA/RNA Synthesis Apoptosis Cancer
    WRN inhibitor 20 (Compound 14c) is a WRN degradation agent. WRN inhibitor 20 exhibits strong degradation activity in various cells, such as HCT-116 (DC50 = 1.7 µM), SW-48 (DC50 = 3.0 µM), and SW-480 (DC50 = 5.9 µM) cells. WRN inhibitor 20 exhibits potent anti proliferative, pro apoptotic, migration inhibiting, and DNA damage inducing effects in MSI-H cells. WRN inhibitor 20 can be used for research on cancer .
    WRN-IN-20
  • HY-175244
    SOS1-IN-20

    		SOS1 Ras Potassium Channel Cancer
    SOS1-IN-20 (Compound 12f) is an orally active SOS1 inhibitor with an IC50 of 5.11 nM against KRAS G12C::SOS1. By disrupting the interaction between KRAS and SOS1, SOS1-IN-20 inhibits KRAS activation and downstream signal transduction. SOS1-IN-20 has an IC50 of 253 nM for p-ERK in PC-9 cells and 16.71 μM for hERG channel . SOS1-IN-20 can inhibit the proliferation of tumor cells and has antitumor activity .
    SOS1-IN-20
  • HY-178057
    EGFR-IN-176

    		EGFR Akt Anaplastic lymphoma kinase (ALK) Apoptosis Cancer
    EGFR-IN-176 is an orally active and ATP-competitive EGFR mutant inhibitor (particularly C797S-mediated EGFR triple mutant). EGFR-IN-176 effectively inhibits subsequent AKT signaling and induces apoptosis in Ba/F3 and PC-9 cells expressing EGFR 19del/T790M/C797S and EGFR L858R/T790M/C797S. EGFR-IN-176 selectively inhibits EGFR signaling in cell lines harboring EGFR triple mutation and shows no inhibitory effect against A431 cells that express wild-type EGFR. EGFR-IN-176 can effectively inhibit the enzymatic activity of ALK (IC50 < 0.5 nM). EGFR-IN-176 can be used for the study of non-small cell lung cancer (NSCLC) .
    EGFR-IN-176
  • HY-N8368
    Neotripterifordin

    		HIV Infection
    Neotripterifordin is a inhibitor of HIV. Neotripterifordin has anti-HIV replication activity in H9 lymphocyte cells with an EC50 of 25 nM .
    Neotripterifordin
  • HY-N6080
    Tripterifordin

    		HIV Infection
    Tripterifordin possesses significant anti-HIV replication activities in H9 lymphocyte cells with an EC50 value of 3100 nM, respectively .
    Tripterifordin
  • HY-127078
    Salaspermic acid

    		HIV Others
    Salaspermic acid is a new triterpene acid isolated from Salacia macrosperma Wight. Salaspermic acid is an inhibitor of HIV reverse transcriptase and HIV replication in H9 lymphocyte cells .
    Salaspermic acid
  • HY-117434
    Suberosol

    		HIV Infection
    Suberosol, a C31 lanostane-type triterpene, is an anti-HIV drug. Suberosol shows anti-HIV replication activity in H9 lymphocyte cells with an EC50 of 3 μg/mL .
    Suberosol
  • HY-174596
    Human IL9 mRNA

    		mRNA Inflammation/Immunology
    Human IL9 mRNA encodes the human interleukin 9 (IL9) protein, a cytokine that acts as a regulator of a variety of hematopoietic cells. IL9 stimulates cell proliferation and prevents apoptosis.
    Human IL9 mRNA
  • HY-115937
    c-Met-IN-9

    		c-Met/HGFR Apoptosis Cancer
    c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC50 of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .
    c-Met-IN-9
  • HY-172597
    YL-1-9

    		MDM-2/p53 CDK Apoptosis Cancer
    YL-1-9 is an inhibitor of the degradation of p53 by MDM2 through strong binding to the key hydrophobic pockets of MDM2. YL-1-9 induces cell cycle arrest and apoptosis in breast cancer cells .
    YL-1-9
  • HY-10049A
    CP 122721 hydrochloride

    		Neurokinin Receptor Neurological Disease
    CP 122721 hydrochloride is a potent, non-peptide and selective nonpeptide neurokinin NK1 antagonist, with a pIC50 of 9.8 for human NK1 receptor expressed in IM-9 cells. CP 122721 hydrochloride exhibits anxiolytic and antidepressant-like effects .
    CP 122721 hydrochloride
  • HY-146718
    Tubulin polymerization-IN-9

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-9 is a potent tubulin inhibitor with IC50 of 1.82 μM. Tubulin polymerization-IN-9 causes cell cycle arrest at G2/M phase, and induces cell apoptosis and depolarized mitochondria of K562 cells. Tubulin polymerization-IN-9 has potent anti-vascular and antitumor activities .
    Tubulin polymerization-IN-9
  • HY-163119
    Pim-1 kinase inhibitor 9

    		Pim Cancer
    Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity .
    Pim-1 kinase inhibitor 9
  • HY-167897
    UR-AK49

    		Histamine Receptor Neurological Disease
    UR-AK49 (compound 11) is a human histamine H1 and H2 receptor agonist. UR-AK49 has an EC50 of 23 nM in a GTPase assay with hH2R-Gsalpha fusion protein expressed in Sf9 insect cells. UR-AK49 can be used in neuro-related research .
    UR-AK49
  • HY-174450
    KMT9-IN-1

    		Epigenetic Reader Domain Cancer
    KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma .
    KMT9-IN-1
  • HY-100738R
    Ubiquitin Isopeptidase Inhibitor I, G5 (Standard)

    NSC144303 (Standard)

    		 Apoptosis Reference Standards Cancer
    Ubiquitin Isopeptidase Inhibitor I, G5 (Standard) is the analytical standard of Ubiquitin Isopeptidase Inhibitor I, G5 (HY-100738). This product is intended for research and analytical applications. Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent caspase and apoptosis activator with IC50 values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.
    Ubiquitin Isopeptidase Inhibitor I, G5 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: